White Paper
Global Pediatric Drug Development Collaboration Part Two
70% of medicines given to children have never been studied in pediatric populations. Children who need treatments represent a relatively small…
All Results
White Paper
White Paper
Global Pediatric Drug Development Collaboration Part One
The pharmaceutical industry is unlike any other industry in that the products manufactured can dramatically improve, and even save, lives. This is…
White Paper
Pediatric Product Development Plan
Development of the Pediatric Study Plan (PSP) for the United States Food and Drug Administration and the Pediatric Investigation Plan (PIP) for the…
Case Study
Early Phase Innovative Pediatric Oncology Program Achieves Successful First Multiple Solid Tumors Study
PRA partnered with the sponsor’s new pediatric oncology department on an innovative pediatric oncology program. The program provided early evaluation…
Blog
The RACE for Children Act
In the US, legislation such as the Better Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) have helped to…
Blog
Ask the Experts: How Can We Ensure Pediatric Oncology is at the Forefront of Legislation?
LeAnn joined PRA in October 2018 as a Senior Project Manager, working primarily on oncology clinical trials. We sat down with her to hear her…
Blog
Master Protocols Address Rarity and Patient Limitations for Pediatric Oncology Trials
A lack of suitable pediatric patients to participate in clinical trials is already an issue. With the RACE for Children Act we expect to see an…
Blog
Ask the Experts: How is the Medical Industry Currently Addressing Sickle Cell Disease?
Sickle Cell Disease (SCD) is a disease with few curative treatments that affects people globally. Both young and older patients who struggle with SCD…
Newsletter
Pediatrics Newsletter
This quarterly publication will keep you informed on who we are and what we are doing, as well as on key news in the world of pediatric clinical…
White Paper
Parents as Gatekeepers for Children with Cancer
The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular…